04.08.13
Clarient Diagnostic Services, Inc., a GE Healthcare company, has launched a next-generation sequencing assay focused on solid tumor targets for use in clinical trials. This assay allows researchers to perform prospective and retrospective analysis to better understand which patients will respond to particular therapies in order to aid early research efforts.
This is the first next-generation sequencing assay launched since GE’s acquisition of SeqWright, Inc., a research lab offering nucleic acid sequencing and other genomic services. This new assay targets the 26 most common oncogenes and tumor suppressor genes, selected for their implication in lung, breast, and colon cancers, and melanoma. The assay will be performed at Clarient’s CLIA-certified facility, where reflex and adjunct testing can be performed as necessary.
“Today, pharmaceutical companies are focusing on particular key drivers of cancer to develop targeted therapies,” said Kenneth J. Bloom, MD, chief medical officer, Clarient Diagnostic Services, Inc. “By providing an assay limited to the most relevant and actionable genes in drug development today, we hope to further our mission of bringing clarity to a complex disease and aiding the biopharmaceutical industry in their clinical research endeavors.”
This is the first next-generation sequencing assay launched since GE’s acquisition of SeqWright, Inc., a research lab offering nucleic acid sequencing and other genomic services. This new assay targets the 26 most common oncogenes and tumor suppressor genes, selected for their implication in lung, breast, and colon cancers, and melanoma. The assay will be performed at Clarient’s CLIA-certified facility, where reflex and adjunct testing can be performed as necessary.
“Today, pharmaceutical companies are focusing on particular key drivers of cancer to develop targeted therapies,” said Kenneth J. Bloom, MD, chief medical officer, Clarient Diagnostic Services, Inc. “By providing an assay limited to the most relevant and actionable genes in drug development today, we hope to further our mission of bringing clarity to a complex disease and aiding the biopharmaceutical industry in their clinical research endeavors.”